, Volume 235, Issue 2, pp 393–398 | Cite as

Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study

  • John Hartberg
  • Simone Garrett-Walcott
  • Angelo De Gioannis
Original Investigation



Depressive episodes are the leading cause of mental health-related hospital admissions in Australia, and 44% of those admitted have a previous history of hospitalisations for depression (Admitted patient mental health-related care: (Australian Institute of Health and Welfare Aust Hospital Stat 2011–12, 2013). Despite numerous available antidepressant treatments, many patients do not respond to conventional therapy, having what is called ‘treatment resistance’ (Fava Biol Psychiatry 53:649–659, 2003). In recent years, ketamine has risen to prominence as an effective, rapidly acting antidepressant (Ketamine: a light in the darkness: Paleos and Ross 28–33, 2013). However, customary intravenous (IV) and intramuscular (IM) routes of administration and relapse rates after cessation remain barriers to more widely adopted usage.


This study represents the largest retrospective review of patients receiving long-term oral ketamine for treatment-resistant depression and post-traumatic stress disorder (PTSD). Our purpose was to examine the safety and efficacy of oral ketamine therapy in an outpatient setting as measured by changes in hospitalisation for psychiatric episodes.


Hospital records of 37 patients who received oral ketamine treatment were reviewed to compare the number and duration of psychiatric hospital admissions before and after treatment. Records were also screened for adverse medical events and changes in ketamine dosage over time.


Following treatment, inpatient hospital days were reduced by 70%, and hospital admissions were reduced by 65%. The dose of ketamine patients required was stable over time with no evidence of tolerance building. There were no serious adverse events and no long-term negative effects associated with ketamine.


Oral ketamine offers a promising pharmacologic adjunct to depression treatment. It may offer a more approachable alternative to IV or IM ketamine. The results warrant further investigation into the safety and efficacy of oral ketamine for psychiatric treatment.


Treatment resistant depression PTSD Oral ketamine 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2009) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67(2):139–145. Google Scholar
  2. Australian Institute of Health and Welfare (2013) Admitted patient mental health-related care: Australian hospital statistics 2011–12, 5Google Scholar
  3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354. CrossRefPubMedGoogle Scholar
  4. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H (2001) Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 6(4):12–16. CrossRefPubMedGoogle Scholar
  5. Broughton PF, Waldron BA (1983) Ketamine hypertension and the renin-angiotensin system. Clin Exp Hypertens 5(6):875–883. Google Scholar
  6. Canterbury District Health Board (2015) Complications of peripheral intravenous therapy. Accessed 21 Oct 2016
  7. Chu PSK, Kowk SC, Lam KM, Chu TY, Chan SWH, Man CW, Ma WK et al (2007) ‘Street ketamine’–associated bladder dysfunction: a report of ten cases. Hong Kong Med J 13(4):311–313PubMedGoogle Scholar
  8. Columbia University (n.d.) Module 01: advanced pain control and sedation. Accessed 21 Oct 2016
  9. Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659. CrossRefPubMedGoogle Scholar
  10. García-Larrosa A, Castillo C, Ventura M, Lorente JA, Bielsa O, Arango O (2012) Cystitis and ketamine associated bladder dysfunction. Actas Urológicas Españolas 36(1):60–64. CrossRefPubMedGoogle Scholar
  11. GraphPad Software. (n.d) GraphPad Prism version 7.0c for Mac. La Jolla, California.Google Scholar
  12. Grégoire M-C, MacLellan DL, Finley GA (2008) A pediatric case of ketamine-associated cystitis (Letter-to-the-Editor RE: Shahani R, Streutker C, Dickson B, et al: ketamine-associated ulcerative cystitis: a new clinical entity. J. Urol. 69: 810–812, 2007). Urology 71(6):1232–1233.
  13. Hides L, Lubman DI, Devlin H, Cotton S, Aitken C, Gibbie T, Hellard M (2007) Reliability and validity of the Kessler 10 and Patient Health Questionnaire among injecting drug users. Aust N Z J Psychiatry 41(2):166–168. CrossRefPubMedGoogle Scholar
  14. Jansen KLR (2000) A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32(4):419–433. CrossRefPubMedGoogle Scholar
  15. Kurdi MS, Theerth KA, Deva RS (2014) Ketamine: current applications in anesthesia, pain, and critical care. Anesth: Essays and Res 8(3):283–290. Google Scholar
  16. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115. CrossRefPubMedGoogle Scholar
  17. Microsoft Corporation (n.d.) Microsoft Excel version 15.20 for Mac. Redmond, WashingtonGoogle Scholar
  18. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charnet DS, Iosifescu DV (2012) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74(4):250–256. CrossRefPubMedPubMedCentralGoogle Scholar
  19. Paleos CA, Ross S (2013) Ketamine: a light in the darkness. Multidisciplinary Association for Psychedelic Studies Bulletin, Special Edition, Spring: 28–33Google Scholar
  20. Price RB, Nock MK, Charney DS, Mathew SJ (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66(5):522–526. CrossRefPubMedPubMedCentralGoogle Scholar
  21. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ et al (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27(5):444–450. CrossRefPubMedGoogle Scholar
  22. Schak KM, Vande Voort JL, Johnson EK, Kung S, Leung JG, Rasmussen KG, Palmer BA, Frye MA (2016) Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 173(3):215–218. CrossRefPubMedGoogle Scholar
  23. Schoevers RA, Chaves TV, Balukova SM, aan het Rot M, Kortekaas R (2016) Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry 208:108–113. CrossRefPubMedGoogle Scholar
  24. Shahani R, Streutker C, Dickson B, Stewart RJ (2007) Adult urology ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69(5):810–812. CrossRefPubMedGoogle Scholar
  25. World Health Organization (2015) WHO model list of essential medicines. Accessed 21 Oct 2016

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.School of MedicineUniversity of QueenslandBrisbaneAustralia
  2. 2.Fellow of Royal Australian and New Zealand College of PsychiatristsMelbourneAustralia
  3. 3.Visiting Fellow, School of Health ScienceQueensland University of TechnologyBrisbaneAustralia

Personalised recommendations